BIOCON notification to the exchange
“This is to inform you that the European Directorate for the Quality of Medicines & HealthCare
(EDQM) conducted a GMP inspection of an API manufacturing site of Biocon Limited in Bangalore
from the 12th to 14th of September 2022 and issued a list of deficiencies on 5
th October 2022. There
were no critical deficiencies and one deficiency cited under the category ‘Major’. We will be
responding to the agency with appropriate corrective and preventive actions within the stipulated
time. Biocon remains committed to the Quality, Safety & Efficacy of its products.”
Off late, we see many such repeated observations on their manufacturing facilities across various global locations. Is Biocon losing the sheen and not focusing on the quality aspects in chase of volumes?
| Subscribe To Our Free Newsletter |
